Federated Hermes Inc. Buys 1,674 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Federated Hermes Inc. lifted its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 127,752 shares of the biotechnology company’s stock after acquiring an additional 1,674 shares during the period. Federated Hermes Inc. owned approximately 0.17% of Axon Enterprise worth $33,002,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. American Century Companies Inc. raised its position in Axon Enterprise by 103.8% in the 1st quarter. American Century Companies Inc. now owns 6,194 shares of the biotechnology company’s stock valued at $853,000 after buying an additional 3,155 shares during the last quarter. Private Advisor Group LLC grew its stake in shares of Axon Enterprise by 40.3% during the 1st quarter. Private Advisor Group LLC now owns 3,458 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 994 shares in the last quarter. Great West Life Assurance Co. Can raised its holdings in shares of Axon Enterprise by 12.3% in the first quarter. Great West Life Assurance Co. Can now owns 37,062 shares of the biotechnology company’s stock valued at $5,247,000 after purchasing an additional 4,048 shares during the last quarter. Raymond James Trust N.A. lifted its position in shares of Axon Enterprise by 4.7% in the first quarter. Raymond James Trust N.A. now owns 3,753 shares of the biotechnology company’s stock worth $517,000 after purchasing an additional 168 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Axon Enterprise by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 236,287 shares of the biotechnology company’s stock worth $32,545,000 after purchasing an additional 4,897 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AXON. Argus started coverage on shares of Axon Enterprise in a research note on Wednesday, March 13th. They issued a “buy” rating and a $380.00 price target on the stock. JMP Securities upped their target price on Axon Enterprise from $250.00 to $285.00 and gave the stock a “market outperform” rating in a report on Tuesday, February 6th. TheStreet downgraded Axon Enterprise from a “b” rating to a “c+” rating in a research note on Tuesday, February 27th. JPMorgan Chase & Co. boosted their price target on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research report on Thursday, April 11th. Finally, The Goldman Sachs Group upped their price objective on Axon Enterprise from $297.00 to $339.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $312.64.

Axon Enterprise Trading Down 1.3 %

Shares of Axon Enterprise stock opened at $293.61 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.00 and a quick ratio of 2.66. The business has a fifty day simple moving average of $300.87 and a two-hundred day simple moving average of $258.44. Axon Enterprise, Inc. has a 1 year low of $175.37 and a 1 year high of $329.87. The company has a market capitalization of $22.16 billion, a price-to-earnings ratio of 127.65 and a beta of 0.93.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.29. The company had revenue of $432.14 million during the quarter, compared to analysts’ expectations of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. Research analysts forecast that Axon Enterprise, Inc. will post 2.44 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.